Opis: Antithrombotic Drug Therapy in Cardiovascular Disease - A Askari

Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, "Antithrombotic Drug Therapy in Cardiovascular Disease" carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, "Antithrombotic Drug Therapy in Cardiovascular Disease" presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT). From the reviews: Despite substantial therapeutic progress, considerable morbidity and mortality remains associated with thrombotic events but rapid expansion of the available armamentarium to combat pathologic thrombosis is nicely summarized in this excellent new book which becomes a valuable guide to improved therapy. The experts from the field, selected by its editors, survey individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors). The treatments discussed are up-to-date methods for management of common cardiovascular thrombotic problems designed for appropriate clinical use. Numerous illustrations, tables and figures throughout the book become particularly helpful for the reader. There are seven major divisions covered by twenty four chapters; most of which are multi-authored and include: Basic Principles, Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease, Antithrombotic Therapy for NSTE ACS, Antithrombotic Therapy for STEMI. Antithrombotic Therapy in Interventional Cardiology, Antithrombotic Therapy in Venous Thromboembolism, and Clinical Considerations. The coagulationist should find this text to be a valuable addition to his/her office reference book shelf. William H Wehrmacher MD FACP FACC Harry L Messmore MD FACP from Comprehensive Therapy - 2010 "The chapter authors of this multiauthored book on antithrombotic drug therapy in cardiovascular disease are national and international thought leaders in their respective fields. ... The intended audience includes medical students, allied health professionals, physicians in training, and cardiovascular physicians. ... This will be a valuable resource for healthcare providers in the field of cardiovascular disease management. The authors have met their objective of providing a high quality, evidence-based review of this field." (Timir Paul, Doody's Review Service, March, 2009)Part 1: Basic Principles Chapter 1 The Platelet in Arterial and Venous Thrombosis Peter Kelly, MD Edward F. Plow, PhD Chapter 2 The Coagulation Cascade in Arterial and Venous Thrombosis Kandice Marchant, MD, PhD Chapter 3 The Link Between Thrombosis and Inflammation John H. Cleator, MD Mark Robbins, MD Chapter 4 Genetics of Thrombosis Svati H. Shah, MD, MHS Richard C. Becker, MD Part II: Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease Chapter 5 Aspirin for Primary and Secondary Prevention Jinesh Kochar, MD, MPH J, Michael Gaziano, MD, MPH Chapter 6 Thienopyridines in Stable CAD Patients Dipak Kotecha, MBChB., MRCP. Marcus D. Flather, MBBS, FRCP Part III: Antithrombotic Therapy for NSTE ACS Chapter 7 Anti-platelet Therapies: Aspirin, Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors Saif Anwaruddin MD Deepak L. Bhatt MD Chapter 8 Unfractionated Heparin and Enoxaparin Pierluigi Tricoci, MD, MHS, PhD Kenneth W. Mahaffey, MD Chapter 9 The Direct Thrombin Ihibitors Tyler Taigen, MD James Harvey, MD A. Michael Lincoff, MD Chapter 10 Synthetic Factor Xa Inhibition, Fondaparinux Michael S. Kim, MD Robert L. Page, Pharm.D Ivan P. Casserly, MBBCh Part IV: Antithrombotic Therapy for STEMI Chapter 11 Antiplatelet Therapies: Aspirin,Clopidogrel and thienopyridines and Glycoprotien IIb/IIIa Inhibitors Rory B. Weiner, MD Marc S. Sabatine, MD, MPH Chapter 12 Antithrombin Therapies: Unfractionated Heparin, Enoxaparin, Direct Thrombin Inhibitors, Fondaparinux John M. Galla, MD Arman T. Askari, MD Chapter 13 Fibrinolysis and Facilitated PCI Ryan D. Christofferson, MD Sorin J. Brener, MD Part V: Antithrombotic Therapy in Interventional Cardiology Chapter 14 Antithrombotic Therapy in Percutaneous Coronary Intervention Adrian W. Messerli, MD Chapter 15 Antithrombotic Therapy in Carotid and Peripheral Intervention Thomas J. Helton, MD Samir R. Kapadia, MD Chapter 16 Monitoring of Antithrombotic Therapies Kristofer Dosh, MD Steven Steinhubl, MD Part VI: Antithrombotic Therapy in Venous Thromboembolic Disease Chapter 17 Antithrombotic Therapy for DVT/PE Esther S.H. Kim, MD John R. Bartholomew, MD Chapter 18 Fibrinolysis for PE Stavros V. Konstantinides, MD Chapter 19 Duration of Anticoagulation Following VTE Clive Kearon, MB MRCPI FRCPC PhD Part VII: Clinical Considerations Chapter 20 Antithrombotic Therapy for Atrial Fibrillation Carmel M. Halley MD Allan L. Klein MD Chapter 21 Antithrombotic Therapy for Valvular Heart Disease Noah Rosenthal MD Brian D. Hoit MD Chapter 22 Antithrombotic Therapy for Cardiomyopathy Zuheir Abrahams MD PhD George Sokos MD W. H. Wilson Tang MD Chapter 23 Heparin-Induced Thrombocytopenia John R. Bartholomew, MD Chapter 24 "Resistance" to Antiplatelet Therapies Gerald C. Koenig, MD, PhD Hitinder S. Gurm, MD

Szczegóły: Antithrombotic Drug Therapy in Cardiovascular Disease - A Askari

Tytuł: Antithrombotic Drug Therapy in Cardiovascular Disease
Autor: A Askari
Producent: Humana Press
ISBN: 9781603272346
Rok produkcji: 2009
Ilość stron: 490
Oprawa: Twarda
Waga: 1.35 kg

Recenzje: Antithrombotic Drug Therapy in Cardiovascular Disease - A Askari